Price alert —
Sign in to get a one-time email the moment ENOV crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · ENOV
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.6B | $-0.0B | $0.0B | $-0.0B | -1.5% | 1.6% |
| 2025-12-31 | $0.6B | $-0.5B | $0.0B | $0.0B | -90.4% | 8.4% |
| 2025-09-30 | $0.5B | $-0.6B | $-0.0B | $0.0B | -104.1% | -1.5% |
| 2025-06-30 | $0.6B | $-0.0B | $-0.0B | $0.0B | -6.5% | -2.8% |
| 2025-03-31 | $0.6B | $-0.1B | $-0.0B | $-0.0B | -10.0% | -7.7% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare ENOV vs peers
Line ENOV up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with ENOV
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-07 | 0.89 | 0.81 | +9.9% | -2.7% |
| 2026-02-26 | 0.95 | 0.84 | +13.1% | +0.2% |
| 2025-11-06 | 0.75 | 0.65 | +15.6% | -1.3% |
| 2025-08-07 | 0.79 | 0.72 | +9.9% | -0.3% |
| 2025-05-08 | 0.81 | 0.74 | +8.9% | -0.1% |
| 2025-02-26 | 0.98 | 0.92 | +7.0% | -4.7% |
| 2024-11-06 | 0.73 | 0.61 | +18.9% | +2.0% |
| 2024-08-07 | 0.62 | 0.59 | +4.5% | +7.4% |
| 2024-05-02 | 0.50 | 0.48 | +3.4% | -1.6% |
| 2024-02-22 | 0.79 | 0.74 | +6.8% | -1.5% |
| 2023-11-07 | 0.56 | 0.54 | +4.0% | -0.2% |
| 2023-08-03 | 0.61 | 0.52 | +18.4% | +0.5% |
| 2023-05-04 | 0.44 | 0.38 | +16.8% | -0.2% |
| 2023-02-23 | 0.72 | 0.66 | +9.9% | -3.1% |
| 2022-11-02 | 0.59 | 0.48 | +22.9% | +6.8% |
| 2022-08-04 | 0.59 | 0.50 | +18.0% | +2.2% |
| 2022-05-10 | 0.37 | 0.35 | +5.7% | -0.6% |
| 2022-02-22 | 1.77 | 1.74 | +2.0% | -0.5% |
| 2021-11-04 | 1.62 | 1.61 | +0.3% | +0.4% |
| 2021-07-28 | 1.68 | 1.61 | +4.5% | +2.9% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| ENOV ★ | $2B | — | 6.6 | 0.7 | 7.9 | 1.1 | 61.0% | 5.4% | — | 13.28% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 59.65%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 9,936,469 | 17.26% |
| American Century Companies Inc | 4,768,921 | 8.28% |
| Vanguard Portfolio Management LLC | 3,808,629 | 6.62% |
| Vanguard Capital Management LLC | 2,552,351 | 4.43% |
| Dimensional Fund Advisors LP | 2,545,922 | 4.42% |
| Rubric Capital Management LP | 2,453,265 | 4.26% |
| State Street Corporation | 2,402,235 | 4.17% |
| Davenport & Co LLC | 2,341,521 | 4.07% |
| Paradigm Capital Management | 1,776,715 | 3.09% |
| Hood River Capital Management LLC | 1,756,669 | 3.05% |
Insider activity · 90d
15 buys / 0 sells · ratio 15.0 · Finnhub
- Ortiz Christine BUY 25,857
- Engert Oliver BUY 53,640 @ $20.92
- Engert Oliver BUY 52,640 @ $20.99
- Engert Oliver BUY 51,840 @ $21.75
- Engert Oliver BUY 50,840 @ $20.99
- Engert Oliver BUY 50,640 @ $23.00
- Engert Oliver BUY 49,640 @ $22.22
- Shirley Brady BUY 110,589
- Bodem Barbara W. BUY 24,201
- Okala Philip BUY 24,201
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-01 | 4 | view · |
| 4 | 2026-06-16 | 4 | view · |
| 4 | 2026-06-15 | 4 | view · |
| 4 | 2026-06-11 | 4 | view · |
| 4 | 2026-06-03 | 4 | view · |
| 4 | 2026-05-21 | 4 | view · |
| 4 | 2026-05-21 | 4 | view · |
| 4 | 2026-05-21 | 4 | view · |
| 4 | 2026-05-21 | 4 | view · |
| 4 | 2026-05-21 | 4 | view · |
| 4 | 2026-05-21 | 4 | view · |
| 4 | 2026-05-21 | 4 | view · |
| 4 | 2026-05-21 | 4 | view · |
| 4 | 2026-05-21 | 4 | view · |
| 8-K | 2026-05-19 | 8-K | view · |
| 4 | 2026-05-14 | 4 | view · |
| 4 | 2026-05-14 | 4 | view · |
| 10-Q | 2026-05-07 | 10-Q | view · |
| 8-K | 2026-05-07 | 8-K | view · |
| DEF 14A | 2026-04-06 | DEF 14A | view · |
| 4 | 2026-04-02 | 4 | view · |
| 4 | 2026-03-16 | 4 | view · |
| 4 | 2026-03-12 | 4 | view · |
| 4 | 2026-03-10 | 4 | view · |
| 4 | 2026-03-10 | 4 | view · |
| 4 | 2026-03-10 | 4 | view · |
| 4 | 2026-03-10 | 4 | view · |
| 4 | 2026-03-10 | 4 | view · |
| 4 | 2026-03-10 | 4 | view · |
| 4 | 2026-03-10 | 4 | view · |
| 4 | 2026-03-10 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-05 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 10-K | 2026-02-26 | 10-K | view · |
| 8-K | 2026-02-26 | 8-K | view · |
| 4 | 2026-01-16 | 4 | view · |
| 8-K | 2026-01-12 | 8-K | view · |
| 4 | 2026-01-05 | 4 | view · |
| 8-K | 2025-12-15 | 8-K | view · |
| 4 | 2025-12-11 | 4 | view · |
| 8-K | 2025-12-10 | 8-K | view · |
| 4 | 2025-11-28 | 4 | view · |
| 8-K | 2025-11-14 | 8-K | view · |
| 10-Q | 2025-11-06 | 10-Q | view · |
| 8-K | 2025-11-06 | 8-K | view · |
| 4 | 2025-10-01 | 4 | view · |
About ENOV
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and f…
Options picks · ENOV
ITM + OTM ideas from the latest scanLoading…
Congress trades · ENOV
STOCK Act disclosuresLoading…
SEC filings & insiders · ENOV
EDGAR · liveLoading…
Holders · ENOV
Institutions & insider activityLoading…